Pluristem Therapeutics Stock Price - PSTI

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 3.37 ▼ -0.04 (-1.17%)
Company Name Stock Ticker Symbol Market Type
Pluristem Therapeutics Inc PSTI NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.08 -2.29% 3.41 3.51 3.38 3.51 3.49 19:59:39
Bid Price Ask Price Spread Spread % News
3.00 14.89 11.89 79.85% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
166 23,340 $ 3.44 $ 80,330 64,800 3.11 - 11.90
Last Trade Time Type Quantity Stock Price Currency
16:48:18 formt 150 $ 3.37 USD

Pluristem Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 53.58M 15.71M $ -26.13M -28.97 - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 307.14k 10.80%

more financials information »

Pluristem Therapeutics News

Loading Messages....

Latest PSTI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PSTI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.783.833.383.5946,739-0.37-9.79%
1 Month3.284.673.113.5656,5950.133.96%
3 Months4.264.673.113.5450,524-0.85-19.95%
6 Months5.706.9983.114.94164,628-2.29-40.18%
1 Year8.45111.903.116.71309,475-5.04-59.65%
3 Years15.3021.203.1111.69344,206-11.89-77.71%
5 Years25.93637.803.1113.87288,494-22.53-86.85%

Pluristem Therapeutics Description

Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Pluristem operates through the single business segment being Development of placenta-based cell therapy product.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.